Q1 beat adds momentum to the recent share price rally
15/05/24 -"The Q1 results surpassed the consensus estimates, driven by a sustained strong performance from the strategic products. The management nonetheless maintained the 2024 outlook. Despite the share price ..."
Pages
56
Language
English
Published on
15/05/24
You may also be interested by these reports :
30/10/26
Investors hailed the Q3 profitability beat and the announcement of a cost savings initiative. The generic erosion of some CVRM medicines was ...
30/10/26
The Q3 beat was impressive and a guidance upgrade to boot cheered up investors. As usual, the all-important immunology medicine Dupixent remained a ...
29/10/26
The Q3 EBITDA was somewhat ahead of expectations, unlike sales. While lower demand in Spain and loss of exclusivity in Japan impaired Bilastine’s ...
29/10/26
After increasing both our DCF and NAV estimates by >20% (discussed in the respective sections), we maintain a Reduce recommendation with c.2% ...